Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3541021 | 0.90 | F10 (0.49) | F10JAK2JAK1TYK2JAK3 | |
| SCHEMBL3539773 | 0.85 | F10 (0.50) | F10MTOR | |
| SCHEMBL3539776 | 0.81 | F10 (0.67) | F10 | |
| SCHEMBL8266510 | 0.80 | F10 (0.68) | F10 | |
| SCHEMBL3539384 | 0.78 | F10 (0.66) | F10 | |
| SCHEMBL5628651 | 0.73 | F10 (0.53) | F10JAK2JAK1TYK2JAK3 | |
| SCHEMBL5625173 | 0.73 | F10 (0.53) | F10JAK2JAK1TYK2JAK3 | |
| SCHEMBL5628665 | 0.72 | F10 (0.50) | F10MTOR | |
| SCHEMBL5625187 | 0.72 | F10 (0.50) | F10MTOR | |
| SCHEMBL4592257 | 0.72 | F10 (0.46) | F10MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146550-A1 | HETEROARYLACETAMIDE INHIBITORS OF FACTOR Xa | BOEHRINGER MARKUS | 2008-06-19 | — | — | US | claimed |
| US-7718659-B2 | Heteroarylacetamide inhibitors of factor Xa | HOFFMANN-LA ROCHE INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080146550-A1 | HETEROARYLACETAMIDE INHIBITORS OF FACTOR Xa | BOEHRINGER MARKUS | 2008-06-19 | — | — | US | disclosed |
| EP-1846381-B1 | HETEROARYLACETAMIDES AS FACTOR Xa INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-05-28 | — | — | EP | disclosed |
| US-7361672-B2 | Heteroarylacetamide inhibitors of factor Xa | HOFFMANN-LA ROCHE INC. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1846381-A2 | NOVEL HETEROARYLACETAMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-24 | — | — | EP | disclosed |
| US-20060142362-A1 | Pyrazoles, triazoles, or tetrazoles substituted with an aryl- or heteroarylcarbonylamino group and an aminocarbonylmethyl group: 5-chloro-thiophene-2-carboxylic acid (1-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-methyl}-1H-[1,2,4]triazol-3-yl)-amide; improved selectivity towards thrombin | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | US | disclosed |
| WO-2006066778-A2 | NOVEL HETEROARYLACETAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146550-A1 | HETEROARYLACETAMIDE INHIBITORS OF FACTOR Xa | F12, TFPI, F2 | F10 9/4885JAK2 769/4885JAK1 1991/4885 |
| US-20060142362-A1 | Pyrazoles, triazoles, or tetrazoles substituted with an aryl- or heteroarylcarbonylamino group and an aminocarbonylmethyl group: 5-chloro-thiophene-2-carboxylic acid (1-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-methyl}-1H-[1,2,4]triazol-3-yl)-amide; improved selectivity towards thrombin | F2, TFPI, F11 | F10 24/4885JAK2 101/4885JAK1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.